Treatment of White Coat Hypertension With Metformin

Basit Öğe Kaydı
dc.authoridSEVINC, ALPER/0000-0002-0499-8918
dc.contributor.authorHelvaci, Mehmet Rami
dc.contributor.authorSevinc, Alper
dc.contributor.authorCamci, Celalettin
dc.contributor.authorYalcin, Atilla
dc.date.accessioned2024-09-18T21:00:43Z
dc.date.available2024-09-18T21:00:43Z
dc.date.issued2008
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractWhite coat hypertension (WCH) is most likely a disorder associated with metabolic syndrome. The study was performed at the Internal Medicine Polyclinic of Dumlupinar University on routine check-up patients. WCH cases who were overweight or obese and desiring weight loss were divided into two subgroups according to whether they preferred to achieve weight loss by medication or diet therapy. The study included 324 cases (204 females) with WCH, 45 of whom were in normal weight range. Therefore, 86.1% (279) of cases with WCH were either overweight or obese, and 41.3% (134) of all WCH cases had dyslipidemia. Twenty-five cases (14.7%) stopped metformin therapy due to excessive anorexia. At the end of a 6-month period, there were highly significant differences between the two groups with respect to the prevalences of resolved WCH, hyperbetalipoproteinemia, hypertriglyceridemia, dyslipidemia, overweight and obesity, and decreased fasting plasma glucose below 110 mg/dL (P < 0.001 for all). Due to gradually increased prevalences of impaired glucose tolerance, type 2 diabetes mellitus, dyslipidemia, excess body weight, and obesity-like disorders from sustained normotension towards WCH and hypertension (HT) cases, and very high prevalences of excess weight and dyslipidemia in the WCH group, WCH may be an associated disorder of metabolic syndrome rather than just being a predisposing factor of atherosclerosis or HT alone. Thus, the management of WCH should not focus solely on the regulation of blood pressure with anti hypertensive medications, but rather on the prevention of future excess weight and various associated disorders, and metformin alone is an effective therapeutic option, most likely due to its powerful inhibitory effect on appetite. (hit Heart J 2008; 49: 671-679)en_US
dc.identifier.doi10.1536/ihj.49.671
dc.identifier.endpage679en_US
dc.identifier.issn1349-2365
dc.identifier.issn1349-3299
dc.identifier.issue6en_US
dc.identifier.pmid19075483en_US
dc.identifier.scopus2-s2.0-60249084751en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage671en_US
dc.identifier.urihttps://doi.org/10.1536/ihj.49.671
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12836
dc.identifier.volume49en_US
dc.identifier.wosWOS:000262914400004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInt Heart Journal Assocen_US
dc.relation.ispartofInternational Heart Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectWhite coat hypertensionen_US
dc.subjectMetforminen_US
dc.subjectDyslipidemiaen_US
dc.subjectExcess weighten_US
dc.titleTreatment of White Coat Hypertension With Metforminen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
141.49 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu